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BAckground:: Worldwide the judiciary branch has been an active player in pub-
lic health policies, especially regarding drugs. In Brazil, this is a huge concern. 
This abstract presents an evaluation of the judicial response to cases regarding 
three biological drugs: etanercept (enbrel), infliximab (remicade) and adalimumab 
(humira), all TNF inhibitor agents for the treatment of patients with autoimmune 
diseases. oBjectives: To identify the prevalence of scientifically grounded judi-
cial decisions and the knowledge of Brazilian judges regarding clinical protocols, 
evidence-based medicine and health technology assessment. Methods: Electronic 
databases of the Supreme Court (STF), the Superior Court of Justice (STJ) and all 
Federal Regional Courts (TRFs) were searched using the keywords “etanercept” 
(enbrel), “infliximab” (remicade) and “adalimumab” (humira). results: 102 judicial 
decisions were found: 6 collegial judgments (6%) and 96 monocratic decisions (94%). 
Of these, 29 were excluded due to procedural reasons (28%) and 73 met the eligibility 
criteria (72%). Of those 73, 69 decisions (95%) determined that government have to 
supply the medications. Only 2 decisions (2.5%) considered it improper to supply the 
drug due to a lack of evidence regarding its effectiveness. Additionally, 2 decisions 
(2.5%) determined the need for forensic expertise. Out of the 73 decisions examined, 
65 did not rely on scientific evidence. Another 2 referred to evidence-based medi-
cine, without, however, taking it as a plea for the decision-making process. Only 2 
decisions considered evidence as a basis for decision-making. On the other hand, 
just 4 decisions referred to expert medical opinions. conclusions: The judiciary 
branch does not rely on scientific evidence or health technology assessment as a 
tool to the decision-making process. In order to preserve the right to health and the 
public health system´s sustainability, it is necessary to employ medical evidence 
methods in judicial decisions.
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oBjectives: The American College of Medical Genetics (ACMG) recommended 
expanding and standardizing the group of rare conditions in US newborn screening 
(NBS) in 2006. This research examines the correspondence between ACMG recom-
mendations and state implementation and contrasts this with Europe. Methods: 
We collected historical data on conditions screened in state programs. We defined 
conditions as Recommended (R list) based on whether a condition was in ACMG’s 
Core of 29 conditions plus 25 secondary conditions groupings. We then assessed 
each state’s (plus D.C.) correspondence with ACMG recommendations. We also 
collected data from Europe. results: The mathematical union of all conditions 
screened in the 51 US geographies is 74. In 2005, prior to the expansion, geographies 
varied in NBS screening from a low of 4 conditions to a high of 46 (mean= 24). This 
represented a significant increase over that from 10 years earlier (mean= 5; range= 
0-8). Currently, the mean number of conditions screened is 48 (range 31-64). Twenty 
geographies screen for at least 50 of the 54 ACMG recommendations. Only 3 geog-
raphies screen for the complete R list; these 3 and 22 others screen for additional 
conditions not on the R list. All US geographies screen for more than 20 conditions. 
In contrast, recent European data indicate a range from 1 to 29 conditions among 
37 geographies reporting data (mean= 8), with only 6 geographies reporting 20 or 
more. conclusions: The expansion of NBS in the US has been a success in terms 
of correspondence with ACMG recommendations with 20 of the 51 US geographies 
adhering to at least 50 of the original 54 ACMG recommendations. The contrast with 
European geographies raises questions about the expansion. Whether it is a positive 
development depends on its costs and health implications.
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oBjectives: This study evaluated the impact of increasing patient access restric-
tions to branded oxycodone hydrochloride controlled-release tablets (OXY) on phy-
sician office visits, pharmacy utilization and costs. Methods: This retrospective 
case-control study of IMS’s medical/pharmacy claims and Formulary Focus database 
analyzed adult patients with ≥ 1 extended-release and long-acting opioid Rx claim 
indexed between 1/1/2009 and 12/31/2011. Patients with ≥ 6 month’s observation in 
pre-restriction or post-restriction periods were analyzed. Cases included patients 
in commercial or Medicare plans imposing access restrictions (tier change [TC] or 
prior-authorization [PA]), thus forming four groups: commercial PA (Com-PA), com-
mercial TC (Com-TC), Medicare PA (MC-PA) and Medicare TC (MC-TC). Controls were 
selected from plans without access restrictions and were matched based on demo-
graphics, clinical characteristics, payer type and index quarter. Pharmacy and office 
visit utilization and costs were measured for 6 months following each patient’s 
index date, comparing the pre- to post-restriction period within each study group. 
Bootstrapping t-test and generalized linear models were utilized to test the differ-
ences in resource utilization and costs. results: The study groups were approxi-
mately 55 years old and 60% female. A significant increase in 6-month office visits 
was observed from the pre to the post-restriction period in plans imposing access 
restrictions: COM-PA (2.13, p< 0.001), COM-TC (1.29, p= 0.017), MC-PA (0.81, p= 0.021), 
MC-TC (1.00, p< 0.001). Total (medical+pharmacy) mean pre to post-restriction cost 
increases of $1,019 (p< 0.001), $433 (p= 0.076), $684 (p< 0.001) and $348 (p< 0.001) were 
also observed in the access restricted groups, respectively. No significant change in 
office visits or costs were observed in the COM-TC, MC-PA or MC-TC control groups, 
however, an increase was observed in the control group matched to the COM-PA 
group for office visits (2.01, p= 0.001) and total costs ($969, p< 0.001). conclusions: 
oBjectives: To examine the association between continuity of care and risk of 
potentially inappropriate concomitant medication (PICM) in continuous non-
steroidal anti-inflammatory drug (NSAID) users. Methods: Longitudinal Health 
Insurance Database 2005 (LHID2005) which contains one million of randomly sam-
pled beneficiaries from National Health Insurance (NHI) in Taiwan was used to 
identify continuous NSAID users who were prescribed with NSAID more than 
30 days in 2005. NSAID’s PICM was defined as if there are significant drug-drug 
interactions (DDI) event based on Drug Interaction Facts. Continuity of care (COC) 
index was used to measure the degree of continuous care for these NSAID users. 
Multiple logistic regression analysis was then applied to estimate the associa-
tion between continuity of care and PICM. results: There were 52,010(5.2% of 
LHID2005) beneficiaries using NSAID more than 30 days in 2005, and 20.2% of 
continuous NSAID users had PICM. Of which, Beta blocking agents was the most 
frequently prescribed and accounted for 8.79% of total PICM. Compared with lower 
level of COC, the odds ratios of PICM were 0.89(95% confidence interval 0.84-0.94) 
and 0.76(95% confidence interval 0.71-0.80) respectively for medium and high 
levels of continuity of care when personal, physician and institutional character-
istics were controlled in logistic regression. conclusions: PICM was common 
for continuous NSAID users in Taiwan, especially in those who had lower level of 
COC. While the consequence of PICM has to be investigated further, health policy 
directed to improvethe continuity of caremay reduce the risk of drug interactions 
in NSAID users.
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oBjectives: CLL is an indolent incurable lymphoma with a widely variable disease 
course. Its treatment is therefore quite heterogeneous. The goal of this project was 
to evaluate the real-world use of individual agents or combination regimens across 
all lines of therapy in CLL during the years 2010-2013 in order to understand the cur-
rent treatment paradigm of CLL. Methods: Treatment records for 110,000 cancer 
patients and over 6.7 million drug administrations were evaluated between August 
2010 and July 2013 at US cancer care facilities participating in a nationwide, commer-
cially available chemotherapy order entry system called IntelliDose®. IntelliDose® 
captures patient demographics, stage, and details of chemotherapy treatment. The 
composition of the 820 oncologists who use IntelliDose® is much like the overall 
population of oncologists in the US, including 54% in private practice and 41% com-
munity hematologist/oncologists. The CLL patients sampled by IntelliDose® were 
projected to a national level for the interpretation of the results. results: The 
average monthly number of CLL patients undergoing any line of treatment was 7,736 
(SD= 565). Of the 3,380 patients receiving first line therapy, the majority of patients 
(n= 810; 24%) were receiving Bendamustine-Rituximab (BR), followed by Fludarabine- 
Cyclophosphamide -Rituximab (FCR) (n= 716; 21%).For relapsed CLL, BR was also the 
most common regimen (18-33% of monthly use), followed by R monotherapy (7- 16% 
of monthly use). Across all lines of therapy, BR is the most common regimen used 
(14-32% monthly use) followed by R alone as the second most common regimen 
(18-25% of monthly use). conclusions: Rituximab is the most frequently used 
agent either as a single agent or in combination, in all lines of CLL treatment in the 
US. Single agent Rituximab is commonly used in CLL therapy in 2nd line and above, 
despite low reported response rates in the literature.
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oBjectives: There are currently 68 orphan drugs with European marketing authori-
zation with orphan designation and 75 orphan drugs without prior orphan des-
ignation in EU. Current Health technology appraisal recommendations in Slovak 
Republic do not include any specific guidelines for reimbursement of orphan drugs 
(OD). Orphan drug reimbursement decisions are made on case-to-case basis and no 
clear rules are currently present. We evaluated market uptake of selected 90 orphan 
drugs and compared it to total market evolution from 2005 to 2012. Methods: Our 
analysis include volume and sales evolution of 90 orphan drugs in Slovak Republic 
from 2005 to 2012 using Health database and publicly available data. results: 
Results show that cumulative 8-years expenditure for selected list of ODs is over 
1,1 billion EUR. The peak sale was reached in 2012 and that sale accounted for 
18,6% from total pharmaceutical spending in 2012. The highest sales growth was 
in 2006 with 33,4% compared to previous year. Until 2009, we have seen strong 
double-digit growth following by still high single digit growth in 2010 (6,1%) and 
2012 (7,6%). Total expenditure represented 10,7%, 12,4%, 12,8%, 13,5%, 14,7%, 15,2%, 
16,5% and 18,6% of total medicine expenditure from 2005 to 2012 in SK, respectively. 
The highest expenditure burden lies on one ATC category: L- antineoplastic and 
immunomodulating agents with 57% share. conclusions: The uptake of orphan 
drugs is according to EU standards very high, but it must be noted that many ODs 
are locally off-patent and generics expand the market. Secondly, we included into 
our selection ODs with and without prior orphan designation. Nevertheless, it is 
important to make more detailed analysis and advocate for prudent reimbursement 
rules for orphan drugs, mainly from local HTA perspective.
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